VSEE HEALTH, INC. (VSEE): Nasdaq/NYSE listing notice — VSee Health receives Nasdaq delisting notice for failure to file 2024 10-K

VSEE HEALTH, INC.

Received Nasdaq notice on April 25, 2025 for non-compliance with Listing Rule 5250(c)(1) due to late Form 10-K.
Has 60 calendar days to submit a compliance plan; Nasdaq may grant up to 180-day extension to October 13, 2025.
Company cites additional time needed to compile audited financials after June 2024 de-SPAC merger.
Trading of VSEE common stock and VSEEW warrants continues; no immediate delisting effect.
No assurance that plan will be submitted or that compliance will be achieved within allowed period.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

VSEE HEALTH, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 25, 2025, VSee Health, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”). The Notice has no immediate effect on the listing of the Company’s Common Stock (Nasdaq: VSEE) or the Company’s public warrants (Nasdaq: VSEEW) on Nasda

View on SEC.gov

Browse all listing & compliance notices →

VSEE HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-046217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.